Luye Announces That Goserelin Microspheres For Injection Received Approval From China's National Medical Products Administration For Treating Breast Cancer; Partnering With Beigene Ltd To Commercialize The Product In Mainland China
Portfolio Pulse from Benzinga Newsdesk
Luye has announced that its Goserelin Microspheres for injection has received approval from China's National Medical Products Administration for treating breast cancer. The company is partnering with Beigene Ltd to commercialize the product in mainland China.
September 11, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beigene Ltd is partnering with Luye to commercialize its newly approved breast cancer treatment in mainland China. This could potentially increase Beigene's market presence and revenues.
The partnership with Luye allows Beigene to commercialize a newly approved product, which could potentially increase its market presence and revenues. This is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 70